Next Article in Journal
Current Overview of Treatment for Metastatic Bone Disease
Previous Article in Journal
COVID-19 Pandemic-Adapted Radiotherapy Guidelines: Are They Really Followed?
Review

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer

1
Faculty of Medicine, Department 4, Cardio-Thoracic Pathology, Carol Davila University of Medicine and Pharmacy, 050471 Bucharest, Romania
2
Department of Internal Medicine and Cardiology, Theodor Burghele Clinical Hospital, 050653 Bucharest, Romania
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(5), 3331-3346; https://doi.org/10.3390/curroncol28050289
Received: 27 July 2021 / Revised: 23 August 2021 / Accepted: 26 August 2021 / Published: 28 August 2021
(This article belongs to the Section Genitourinary Oncology)
Androgen deprivation therapy (ADT) is successfully used in patients with advanced prostatic cancer, but there are many concerns about its systemic side effects, especially due to advanced age and frequent comorbidities in most patients. In patients treated with ADT there are metabolic changes involving the glycaemic control and lipid metabolism, increased thrombotic risk, an increased risk of myocardial infarction, severe arrhythmia and sudden cardiac death. Still, these adverse effects can be also due to the subsequent hypogonadism. Men with heart failure or coronary artery disease have a lower level of serum testosterone than normal men of the same age, and hypogonadism is related to higher cardiovascular mortality. Many clinical studies compared the cardiovascular effects of hypogonadism post orchiectomy or radiotherapy with those of ADT but their results are controversial. However, current data suggest that more intensive treatment of cardiovascular risk factors and closer cardiological follow-up of older patients under ADT might be beneficial. Our paper is a narrative review of the literature data in this field. View Full-Text
Keywords: androgen deprivation therapy; hypogonadism; cardiovascular; thrombotic risk; arrhythmia; QT interval; prostate cancer androgen deprivation therapy; hypogonadism; cardiovascular; thrombotic risk; arrhythmia; QT interval; prostate cancer
Show Figures

Figure 1

MDPI and ACS Style

Gheorghe, G.S.; Hodorogea, A.S.; Ciobanu, A.; Nanea, I.T.; Gheorghe, A.C.D. Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer. Curr. Oncol. 2021, 28, 3331-3346. https://doi.org/10.3390/curroncol28050289

AMA Style

Gheorghe GS, Hodorogea AS, Ciobanu A, Nanea IT, Gheorghe ACD. Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer. Current Oncology. 2021; 28(5):3331-3346. https://doi.org/10.3390/curroncol28050289

Chicago/Turabian Style

Gheorghe, Gabriela S., Andreea S. Hodorogea, Ana Ciobanu, Ioan T. Nanea, and Andrei C.D. Gheorghe 2021. "Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer" Current Oncology 28, no. 5: 3331-3346. https://doi.org/10.3390/curroncol28050289

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop